Provigil Generic Exclusivity Decision “Eviscerates” Hatch-Waxman, FTC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In a strongly worded amicus brief filed in Mylan’s lawsuit against FDA, the Federal Trade Commission says it would have required different remedies in clearing Teva’s acquisition of Cephalon last year had it known the Israel-based firm would receive sole 180-day marketing exclusivity for modafinil.
You may also be interested in...
Teva Gets FTC Okay For Cephalon Deal After Reducing Its Generic Provigil Exclusivity
Federal Trade Commission amends final order settling charges Teva’s acquisition of Cephalon would have been anticompetitive; agency cites Teva’s deal allowing Mylan to launch its generic Provigil 45 days early.
Mylan’s Generic Provigil Will Launch In August Under Teva Deal
The agreement allows Mylan on the market before Teva’s 180-day exclusivity rights for modafinil expire in late September. For Teva, the deal could be a way of appeasing the Federal Trade Commission’s anti-competition concerns over the wakefulness drug.
Musical Tables in Generic Drug Litigation
Generic drug litigation remains a prominent part of food and drug law practices. But with the growing complexity of the case law—and the blurring lines within industry—it is very hard to predict which client and which attorney will be on what side. Back-to-back hearings on Provigil and Vancocin make that clear.